MazdutideWeight LossSafety Rating 7/10

Primary research areaObesity / weight loss

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose range3–9 mg SC once weekly. Phase III: 9 mg/week. Titrated from lower doses. Research compound.
AdministrationVaries
Safety7/10 · Not FDA-approved (Phase III)
NCAA D1Not listed

Price Comparison

Compare vendors · per 5mg

3 vendors competing

VendorPrice$ / mgUpdated
Pantheon PeptidesBest $/mgCOA ✓ · 3P$97.20$108.00−10% · code PEPTIDEPRI10$9.72Apr 23, 2026Buy →
Modern AminosCOA ✓ · 3P$58.00$11.60May 14, 2026Buy →
Pantheon PeptidesCOA ✓ · 3P$64.80$72.00−10% · code PEPTIDEPRI10$12.96Apr 23, 2026Buy →
PureRawzCOA ✓ · 3P$115.97$19.33May 14, 2026Buy →

Overview

About Mazdutide

Mechanism of action

Dual GLP-1 receptor and glucagon receptor (GCGR) agonist; GLP-1 component suppresses appetite and improves glycemia; glucagon component increases energy expenditure, promotes lipolysis, and reduces hepatic fat; weekly injection.

Safety profile

Nausea, vomiting, diarrhea, decreased appetite; glucagon effects may include hyperglycemia at high doses; still in trials. · Phase III trials ongoing; GI side effects; dual agonist; promising efficacy and tolerability

📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Related pages

More on Mazdutide

Failed to fetch